Study identifier:D1522C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomised, Double-blind Placebo-controlled, Parrallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD9056 Administrated for 28 Days in Patients with Osteoarthritis of the Knee
Rheumatoid Arthritis
Phase 2
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|